ARTICLE | Clinical News
Alcobra's MDX on hold
September 28, 2016 7:00 AM UTC
Alcobra Ltd. (NASDAQ:ADHD) said FDA placed a clinical hold on the company's MDX metadoxine ER to treat ADHD and fragile X syndrome, including the Phase III MEASURE study in ADHD. According to Alcobra, FDA said the hold resulted from preclinical studies that showed adverse neurological findings. ...